In vitro studies showed that vandetanib is also active against EGFR-expressing cutaneous squamous carcinoma (SCC) cells (A431, DJM1) [152] and human NSCLC PC-9 cells carrying a deletion in EGFR exon 19 (delE746-A750) [153]. Here, EGFR is linked to non-small cell lung carcinoma.